Soleil Securities Upgrades Savient Pharmaceuticals (SVNT) to Buy; Lowering Krystexxa Estimates, but SVNT is Oversold
Tweet Send to a Friend
Soleil Securities upgrades Savient Pharmaceuticals (Nasdaq: SVNT) from Hold to Buy. PT lowered from $23 to $14.
Soleil analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Soleil analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
